Domestic markets closed lower despite the RBI hinting at a rate cut. TCS is showing strong technical resilience and poised for an upward reversal, making it a ‘buy on dips’ candidate. Natco Pharma is in a healthy consolidation phase with potential targets of Rs 1,650–1,720.
Kaynes shares plunge 43% from October peak. Is a tactical rebound on the cards or more pain ahead?
Kaynes has plunged 43.5% from its October peak, with Friday’s 12.5% drop marking the steepest single-day decline. Momentum indicators remain bearish, signaling a risk of